Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today provides an update on its ongoing negotiations with its creditors and its agreement with its senior creditor, IPF Partners, to file for insolvency (déclaration de cessation des paiements), to request the opening of reorganization proceedings (redressement judiciaire) and to undertake significant corporate governance changes in a short notice.
Context
Failure at the Combined Shareholders' Meeting of February 11, 2025 to approve certain financial delegations, and, in particular, on the issuance of new shares in redemption for bonds redeemable into new or existing shares (ORANE) held, or to be potentially issued and held by IRIS, triggered an event of default under the IRIS and IPF Partners bond financing agreements allowing each of them to request mandatory redemption of the bonds they hold (EUR 4.3 million and EUR 14.2 million, respectively, as of June 30, 2025).
Since then, Poxel's Board and Management have actively engaged in restructuring discussions with creditors to identify a solution that would allow the Company to continue its operations.
At the same time, the Company pursued discussions with several potential partners for the development of its pipeline. In particular, Poxel entered into advanced negotiations with a prospective partner for PXL065. However, given the short cash runway of the Company (which the Company announced on June 30, 2025 to run through the course of July 2025) as well as the foreseeable timeframe required to close this partnership and sale, this plan could not be completed.
As a result, Poxel Management and Board of Directors have agreed to proceed with the following significant structural corporate changes at Poxel, following the filing for insolvency (déclaration de cessation des paiements) and requesting the opening of reorganization proceedings (redressement judiciaire) with the Court for Economic Activities of Lyon.
Estimated Consolidated Cash and Cash Equivalents Position as of June 30, 2025
The Company estimates that its total consolidated cash and cash equivalents as of June 30, 2025, amounted to approximately EUR 1.3 million (unaudited), including EUR 563 thousand corresponding to cash held in security trusts bank accounts to secure their financing for several years, in accordance with the royalty monetization agreement with OrbiMed.
Filing for insolvency (déclaration de cessation des paiements) and for the opening of reorganization proceedings (redressement judiciaire)
On July 29, 2025, Poxel filed for insolvency (déclaration de cessation des paiements) and for the opening of reorganization proceedings (redressement judiciaire) with the Court for Economic Activities of Lyon.
A decision of the court is expected to occur on or after the hearing scheduled on August 5, 2025.
Impact on Governance and Organization
Given the inability to secure support from creditors for its strategic development plan, an agreement between the Board of Directors of Poxel and its senior creditor IPF Partners has been reached to implement the following measures:
Replacement of all the current Board members following their individual resignation by new directors coopted by the Board of Directors in a short notice after the filing for the opening of reorganization proceedings (redressement judiciaire) in front of the Court for Economic Activities of Lyon.
Appointment of a new transition CEO by the new Board of Directors to occur in a short notice after the filing for the opening of reorganization proceedings (redressement judiciaire) in front of the Court for Economic Activities of Lyon.
Implementation of a short-term financial and operational transition plan aimed at ensuring the continuity of Poxel's operations. Existing CEO Thomas Kuhn will provide support to the Company during this transition period.
The Board of Directors of the Company has approved the agreement with IPF Partners which is summarized herein and on the website of the Company under the related party transactions (conventions réglementées) subsections.
Outlook and 2024 annual accounts
Implementation of the steps of the proposed transition plan will be announced as soon as effective, including the change of Governance and the decision of the Court for Economic Activities of Lyon regarding the request for the opening of reorganization proceedings (redressement judiciaire).
Given the current situation, the Company is unable to provide an effective timeline for the approval and publication of its 2024 annual report or the convening of its next Annual General Meeting, which has been postponed as mentioned below.
Suspension of trading
Poxel's shares will be suspended from trading starting July 30, 2025, before market opening and will trade again after the decision of the Court for Economic Activities of Lyon expected to occur on August 5, 2025, or shortly after.
Poxel will continue to inform the market of the next major steps of its reorganization proceedings.
Postponement of Annual General Meeting until December 31, 2025
As already made public on June 30, 2025, the Lyon Court for Economic Activities granted the Company's request to postpone until December 31, 2025, at the latest, the holding of its 2025 Annual General Meeting due to the delay in the approval of its annual statutory and consolidated financial statements for the fiscal year 2024. As a reminder, this delay in the closing and publication of its 2024 annual results resulted from the potential impact of the negotiations with the Company's financial creditors and with potential partners for the development of the Company's pipeline on its financial statements. The holding of the 2025 Annual General Meeting remains subject to the approval by the Board of Directors of the financial statements for the year ended December 31, 2024.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
GEA Raises Forecast for Fiscal Year 2025 and Provides Positive Outlook
DUESSELDORF, Germany--(BUSINESS WIRE)--Due to a very positive operating performance in the first 6 months and expectations for the remainder of the financial year 2025, GEA Group Aktiengesellschaft is raising all guidance parameters based on preliminary figures as follows: Organic sales growth 2 to 4 percent (previously 1 to 4 percent), EBITDA-margin before restructuring expenses 16.2 to 16.4 percent (previously 15.6 to 16.0 percent) and ROCE 34 to 38 percent (previously 30 to 35 percent). The company will publish its complete statement for the 2nd quarter (half-year financial report) on August 7, 2025. 'Our positive development continues. The additional improvements are broad-based, supported by a favorable order situation as well as margin improvements and efficiency gains across the Group. Once again, we are thus demonstrating our strength in executing on our plans,' said GEA CEO Stefan Klebert. Alongside improving the profitability indicators EBITDA margin before restructuring expenses and ROCE, GEA also increased order intake and revenues on an organic basis compared to the prior-year quarter. This was particularly driven by a strong base business. The large order with a volume of between EUR 140 million and EUR 170 million announced by GEA on July 29 will only be booked in the second half of this year. 'Despite the current environment, GEA continues to perform very positively. We anticipate further interesting projects of all sizes in the second half of the year and expect to significantly accelerate our revenue growth in 2026 while further increasing profitability. Against this background, we are confirming our Mission 30 growth and profitability targets,' GEA CEO Stefan Klebert added. NOTES TO THE EDITOR More information about GEA To the GEA Media Center Follow GEA on LinkedIn, YouTube ABOUT GEA GEA is one of the world's largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services. For instance, every second pharma separator for essential healthcare products such as vaccines or novel biopharmaceuticals is produced by GEA. In food, every fourth package of pasta or every third chicken nugget are processed with GEA technology. With more than 18,000 employees, the group generated revenues of about EUR 5.5 billion in more than 150 countries in the 2024 fiscal year. GEA plants, processes, components and services enhance the efficiency and sustainability of customers' production. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company's purpose: 'Engineering for a better world.' GEA is listed on the German MDAX, the European STOXX® Europe 600 Index and is also a constituent of the leading sustainability indices DAX 50 ESG, MSCI Global Sustainability and Dow Jones Best-in-Class World. More information can be found online at pr@
Yahoo
an hour ago
- Yahoo
Availability of 2025 Half-Year Financial Report
Press Release Paris – July 31, 2025 – EUROAPI posted today its 2025 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2025. This document is available for consultation and downloading on EUROAPI's website: This report includes notably the 2025 half-year management report, the consolidated financial statements on 30 June 2025, and the Statutory Auditors' review report on the half-yearly financial information. Financial agenda (all dates to be confirmed) 3 March 2026: FY 2025 Results 27 May 2026: 2026 AGM 28 July 2026: H1 2026 results About EUROAPI EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential therapies inspires our 3,270 employees every day. With strong research and development capabilities and five manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris (ISIN: FR0014008VX5; ticker: EAPI). Find out more at and follow us on LinkedIn. Media Relations contact:Laurence BollackTel. : +33 (0)6 81 86 80 19mr@ Investor Relations contacts:Sophie Palliez-CapianTel. : +33 (0)6 87 89 33 MassonneauTel. : +33 (0)7 60 32 29 Attachment EUROAPI - Press release - July 31, 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Dollar Gains as US Economic Strength Dampens Fed Rate Cut Expectations
The dollar index (DXY00) today is up by +0.23% and posted a fresh 2-month high. The dollar is supported by today's US economic news that shows a resilient labor market with sticky price pressures and labor costs, which are hawkish for Fed policy. The dollar also has carryover support from Wednesday, when Fed Chair Powell dampened expectations of a Fed rate cut in September when he said the labor market "looks solid" and a moderately restrictive monetary policy is appropriate due to inflation risks from tariffs. US weekly initial unemployment claims rose by +1,000 to 218,000, showing a stronger labor market than expectations of 224,000. More News from Barchart Dollar Rallies and Gold Sinks as Powell Pushes Back Against Rate Cuts Solid US Economic Reports Boost the Dollar Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! US Jun personal spending rose +0.3% m/m, weaker than expectations of +0.4% m/m. Jun personal income rose +0.3% m/m, stronger than expectations of +0.2% m/m. The US Jun core PCE price index, the Fed's preferred inflation gauge, rose +2.8% y/y, stronger than expectations of +2.7% y/y. The US Q2 employment cost index rose +0.9%, stronger than expectations of +0.8%. The US Jul MNI Chicago PMI rose +6.7 to a four-month high 47.1, stronger than expectations of 42.0. In the latest tariff news, President Trump said today that he will impose a tariff rate of 15% on imports from South Korea and that a deal with Taiwan was also being drafted as the two countries reached "a certain degree of consensus." In addition, trade deals are in the offing for Thailand and Cambodia after they agreed to a ceasefire. Federal funds futures prices are discounting the chances for a -25 bp rate cut at 40% at the September 16-17 FOMC meeting and 36% at the following meeting on October 28-29. EUR/USD (^EURUSD) today is up by +0.15%. The euro has garnered support from today's economic news that shows strength in the Eurozone labor market after the Jun unemployment rate remained unchanged at a record low of 6.2%. Gains in the euro are limited due to a stronger dollar, and after German Jul CPI rose less than expected at the slowest pace in 10 months, a dovish factor for ECB policy. The Eurozone Jun unemployment rate remained unchanged at a record low of 6.2%, showing a stronger labor market than expectations of a +0.1 point increase to 6.3%. The German Jul unemployment change rose +2,000, showing a stronger labor market than expectations of +15,000. German Jul CPI (EU harmonized) eased to +1.8% y/y from +2.0% y/y in Jun, weaker than expectations of +1.9% y/y and the slowest pace of increase in 10 months. Swaps are pricing in an 11% chance of a -25 bp rate cut by the ECB at the September 11 policy meeting. USD/JPY (^USDJPY) today is up by +0.64%. The yen gave up overnight gains and tumbled to a 4-month low against the dollar on dovish comments from BOJ Governor Ueda, who said the BOJ wasn't in danger of falling behind on inflation after keeping interest rates unchanged, which dampened expectations of a near-term rate hike by the BOJ. An unexpected decline in the Japanese Jul consumer confidence index also weighed on the yen. The yen initially moved higher in overnight trading after the BOJ kept the overnight call rate unchanged at 0.50% but raised its 2025 Japan GDP estimate and 2025 core CPI estimate. Also, today's news that showed stronger-than-expected Japanese industrial production and retail sales was supportive for the yen. The yen continues to be undercut by concerns that the LDP's loss of its majority in Japan's upper house in the July 20 elections may lead to fiscal deterioration in Japan's government finances, as the government boosts spending and implements tax cuts. The Japan Jul consumer confidence index unexpectedly fell -0.8 to 33.7, weaker than expectations of an increase to 35.0. Japan's Jun industrial production unexpectedly rose +1.7% m/m, stronger than expectations of a decline of -0.8% m/m and the biggest increase in four months. Japan's Jun retail sales rose +1.0% m/m, stronger than expectations of +0.5% m/m and the biggest increase in five months. As expected, the BOJ voted 9-0 to keep the overnight call rate unchanged at 0.50%. The BOJ raised its 2025 GDP forecast to 0.6% from 0.5% previously and raised its 2025 core CPI ex-energy estimate to 2.8% from 2.3% previously. BOJ Governor Ueda said the BOJ is continuing with stimulative policy settings even as the price trend rises because the trend is still below its 2.0% target. August gold (GCQ25) today is up +1.80 (+0.05%), and September silver (SIU25) is down -1.089 (-2.89%). Precious metals are mixed today, with silver falling to a 4-week low. Concerns that US tariff policy will undercut global growth are fueling some safe-haven demand for precious metals after President Trump on Wednesday said he will impose a tariff rate of 25% on India starting August 1 and suggested he would add an additional penalty over the country's energy purchases from Russia. Precious metals continue to receive safe-haven support from geopolitical risks, including the conflicts in Ukraine and the Middle East. Gains in precious metals today are limited due to the strength of the dollar. Also, today's US economic news shows a resilient labor market and sticky price pressures and labor costs, which are hawkish for Fed policy and negative for precious metals. In addition, precious metals are being undercut by negative carryover from Wednesday, when Fed Chair Powell said a moderately restrictive monetary policy is appropriate due to inflation risks from tariffs. Silver prices are sharply lower today on negative carryover from a -21% plunge in copper prices today to a 3.5-month low after President Trump excluded refined copper imports from tariffs. Additionally, concerns that Chinese industrial metals demand remains stagnant are undercutting silver prices after China's July manufacturing PMI unexpectedly fell -0.4 to 49.3, weaker than expectations of no change at 49.7. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
